clinical trial · NCT07367971
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Atom Therapeutics Co., Ltd·phase1·recruiting·n = 20
Gout ChronicGoutDDI (Drug-Drug Interaction)ABP-671 plus allopurinol
brief summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
started
Jan 23, 2026
primary completion
Jul 31, 2026
completion
Aug 31, 2026
last updated
Apr 14, 2026
official title
Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol